AstraZeneca Pays Big To Get Into RSV

The UK group buys its first vaccine company, Icosavax, with an eye to its platform technology.  

Vaccine_shutterstock_1272846445_620x413.jpg

Hats off to Icosavax, Inc. – $838m isn’t a bad payday for a company with a single clinical-stage candidate. The vaccine maker has been snapped up by AstraZeneca PLC, and the sizeable upfront payment shows how eager the UK giant is to enter the respiratory syncytial virus (RSV) space, where GSK and Pfizer precede it.

More from Deals

PureTech Weighs Up Pros And Cons Of Going Private

 
• By 

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By 

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy

 

Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.

More from Business

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By 

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

What Is Fuelling Cell And Gene Therapies In India?

 
• By 

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?